Abstract: Method for preventing or treating neuropathic and/or inflammatory pain, wherein said method comprises administering at least one effective dose of the phosphorothioate oligonucleotide IMT504. The preventive method may be applied to a mammal to be subjected to a medical or surgical intervention, or to a mammal that may be injured performing a risky task (for example, a soldier in a battle) to prevent development of pain after a medical intervention or injury.

Abstract: A method for the treatment of post-surgical pain in a patient. The method includes: a) administering at least one effective dose of the phosphorothioate oligonucleotide IMT504 to a mammal prior the surgery. The oligonucleotide IMT504 has the nucleotide sequence set forth in SEQ ID No. 1 and b) post-surgery administer a suboptimal amount of an opioid.

Abstract: In one aspect, provided herein is a nanocarrier composition for formulating a hydrophilic and aromatic low molecular-weight drug (HALMD), the composition comprising: an aromatic polymer; and a hydrophilic and aromatic low molecular-weight drug (HALMD); wherein the aromatic polymer has a positive or negative charge or is a zwitterion, and the hydrophilic and aromatic low molecular-weight drug (HALMD) has an opposing positive or negative charge or is a zwitterion; and wherein the composition has a size of between 50-400 nm and optionally, a zeta potential of from +100 to ?100 mV. A method for preparing the nanocarrier composition, as well as pharmaceutical compositions and therapeutic uses thereof, are also disclosed.

Abstract: Method for preventing or treating neuropathic and/or inflammatory pain, wherein said method comprises administering at least one effective dose of the phosphorothioate oligonucleotide IMT504. The preventive method may be applied to a mammal to be subjected to a medical or surgical intervention, or to a mammal that may be injured performing a risky task (for example, a soldier in a battle) to prevent development of pain after a medical intervention or injury.

Abstract: The present invention relates to a formulation useful to control Listeria monocytogenes that comprises three new lactic acid bacteria, namely Carnobacterium maltaromaticum ATCC® PTA-9380, C. maltaromaticum ATCC® PTA-9381 and Enterococcus mundtii ATCC® PTA-9382 together with the bacteriocin nisin. This formulation is obtained from Inactivated Fermentates (IF) of these strains plus nisin and is designed to be used in the food industry. This formulation is used as an agent with tested antagonistic and bactericidal action against the pathogen Listeria monocytogenes, the microorganism that causes listeriosis, a food-borne disease, in humans. Based on this formulation, 2 surface sanitizing products can be obtained, a liquid and a solid. Both surface sanitizers can be applied to sanitize equipments, devices, working surfaces, gutters and drainages, especially in the food industry.

Abstract: The present invention relates to a formulation useful to control Listeria monocytogenes that comprises three new lactic acid bacteria, namely Carnobacterium maltaromaticum ATCC® PTA-9380, C. maltaromaticum ATCC® PTA-9381 and Enterococcus mundtii ATCC® PTA-9382 together with the bacteriocin nisin. This formulation is obtained from Inactivated Fermentates (IF) of these strains plus nisin and is designed to be used in the food industry. This formulation is used as an agent with tested antagonistic and bactericidal action against the pathogen Listeria monocytogenes, the microorganism that causes listeriosis, a food-borne disease, in humans. Based on this formulation, 2 surface sanitizing products can be obtained, a liquid and a solid. Both surface sanitizers can be applied to sanitize equipments, devices, working surfaces, gutters and drainages, especially in the food industry.

Abstract: The present application is directed to a new Bacillus subtilis strain deposited under the access number ATCC® PTA-8805, to bioproduct formulations comprising viable cells of the new strain, which can be encapsulated or in a concentrated liquid form, and to the use of these bioproducts to biologically control and decrease the incidence of Rhizoctonia solani, a plant pathogen that attacks economically important crops. The bioproducts are applied in encapsulated form directly over tubers or spraying a concentrated liquid form diluted in water over a plantation, and both formulations are applied in covered furrows.